Skip to main content
Premium Trial:

Request an Annual Quote

Kyowa Selects Second Cancer Drug Candidate under Dicerna Partnership

Premium

Dicerna Pharmaceuticals this week announced that partner Kyowa Hakko Kirin has decided to advance a second cancer drug candidate into formal development as part of the companies' ongoing alliance.

The move has triggered a $5 million milestone payment to Dicerna.

The firms began working together in 2010 as part of a deal that gave Kyowa access to Dicerna's Dicer-substrate RNAi technology against cancer targets (GSN 1/7/2010). In 2011, Kyowa chose to develop the first drug candidate worked on under the arrangement and began exploring a second (GSN 12/5/2011). The companies also expanded the partnership to include immunologic and inflammatory diseases.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.